UBS analyst AJ Rice lowered the firm’s price target on CareMax to $2.20 from $6.40 on Friday, while keeping a Neutral rating on the shares. The firm adjusted its model to account for the continuing challenging environment.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMAX: